---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-053527"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2022-02-25T23:59:59+00:00"
generated_at: "2026-06-27T04:03:43.874141+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day

## Summary
- Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.
- Adjusted EBITDA margin target of 28% in 2025, up from 20%+ target set in 2017.
- Previously set 2017 targets of 3-5% revenue growth and 20%+ EBITDA margin were exceeded.
- Growth drivers include ddPCR, single cell analysis, biopharma expansion, and molecular diagnostics.
- Capital allocation strategy includes generating cash flow and pursuing strategic acquisitions.

## SEC filing metadata
- accession: 0001193125-22-053527
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2022-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/0001193125-22-053527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000119312522053527/d901425d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-053527
- JSON: https://secwatch.observer/filing/0001193125-22-053527.json
- Plain text: https://secwatch.observer/filing/0001193125-22-053527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.